Prostate Cancer Screening Program Beneficial in Top Decile of Polygenic Risk Score

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 14, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, April 14, 2025 -- A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically significant disease, according to a study published in the April 10 issue of the New England Journal of Medicine.

Jana K. McHugh, M.B., B.Ch., from the Institute of Cancer Research in London, and colleagues recruited people aged 55 to 69 years from primary care centers in the United Kingdom. Irrespective of prostate-specific antigen (PSA) level, participants with a polygenic risk score in the 90th percentile or higher were invited to undergo prostate cancer screening with multiparametric magnetic resonance imaging (MRI) and transperineal biopsy.

Overall, 745 participants had a score in the 90th percentile or higher and were invited to undergo screening; 468 (62.8) percent underwent MRI and prostate biopsy and 187 (40.0 percent) had prostate cancer detected. The researchers found that 103 of the 187 participants with cancer (55.1 percent) had prostate cancer classified as intermediate or higher risk according to the 2024 National Comprehensive Cancer Network (NCCN) criteria, with treatment indicated. In 74 (71.8 percent) of these participants, cancer would not have been detected according to the diagnostic pathway currently used in the United Kingdom (high PSA level and positive MRI results). Forty participants with cancer (21.4 percent) had disease classified as unfavorable intermediate risk or as high or very high risk according to NCCN criteria.

"Our results show that offering targeted screening to participants in at least the 90th percentile of genetic risk distribution as determined by a polygenic risk score resulted in the detection of prostate cancer warranting clinical management in 55.1 percent of these participants," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-15 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords